Georges Gemayel's Insider Trades & SAST Disclosures
Georges Gemayel's most recent trade in Supernus Pharmaceuticals Inc was a trade of 5,369 Restricted Stock Units done . Disclosure was reported to the exchange on Feb. 22, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Georges Gemayel.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Feb 2025 | 5,369 | 0 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2025 | 5,369 | 18,684 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 7,296 | 7,296 | - | - | Director Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 4,475 | 4,475 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 10,787 | 0 | - | - | Director Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Sale of securities on an exchange or to another person at price $ 36.30 per share. | 08 Nov 2024 | 10,787 | 13,315 (0%) | 0% | 36.3 | 391,568 | Common Stock |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.46 per share. | 08 Nov 2024 | 10,787 | 24,102 (0%) | 0% | 11.5 | 123,619 | Common Stock |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 14,213 | 10,787 | - | - | Director Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.46 per share. | 07 Nov 2024 | 14,213 | 27,528 (0%) | 0% | 11.5 | 162,881 | Common Stock |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Sale of securities on an exchange or to another person at price $ 36.62 per share. | 07 Nov 2024 | 14,213 | 13,315 (0%) | 0% | 36.6 | 520,480 | Common Stock |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2024 | 10,000 | 25,000 | - | - | Director Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Sale of securities on an exchange or to another person at price $ 31.33 per share. | 13 Sep 2024 | 10,000 | 13,315 (0%) | 0% | 31.3 | 313,300 | Common Stock |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.46 per share. | 13 Sep 2024 | 10,000 | 23,315 (0%) | 0% | 11.5 | 114,600 | Common Stock |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Sale of securities on an exchange or to another person at price $ 31.33 per share. | 13 Sep 2024 | 3,886 | 13,315 (0%) | 0% | 31.3 | 121,748 | Common Stock |
| Disc Medicine Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Gemayel Georges | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 3,886 | 17,201 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Gemayel Georges | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 23 Feb 2024 | 3,886 | 0 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Gemayel Georges | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 8,252 | 8,252 | - | - | Director Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 5,369 | 5,369 | - | - | Restricted Stock Units | |
| Disc Medicine Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 7,136 | 7,136 | - | - | Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 6,293 | 6,293 | - | - | Director Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 3,886 | 3,886 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 3,882 | 13,315 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Feb 2023 | 3,882 | 0 | - | - | Restricted Stock Units | |
| Disc Medicine Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2022 | 7,000 | 7,000 | - | - | Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 6,847 | 6,847 | - | - | Director Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 3,882 | 3,882 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2022 | 4,222 | 9,433 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Feb 2022 | 4,222 | 0 | - | - | Restricted Stock Units | |
| Disc Medicine Inc | Georges Gemayel | Director, Executive Chair of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 793,274 | 793,274 | - | - | Stock Option (Right to Buy) | |
| Disc Medicine Inc | Georges Gemayel | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 23,514 | 23,514 | - | - | Stock Option (Right to Buy) | |
| Disc Medicine Inc | Georges Gemayel | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 17,245 | 17,245 | - | - | Stock Option (Right to Buy) | |
| Disc Medicine Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2021 | 45,466 | 45,466 | - | - | Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 7,365 | 7,365 | - | - | Director Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Georges Gemayel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 4,222 | 4,222 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges